ICIs were initially studied and applied for the clinical application in melanoma, and Ipilimumab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), is the first drug in history to significantly prolong the survival period of patients with this highly malignant tumor [47]. Here, CTLA4 is linked to melanoma.